Conor Killmurray | Authors


CG0070 Provides Durable Responses in Certain Patients with Non-Muscle Invasive Bladder Cancer

June 21, 2022

In an interview with Targeted Oncology, Roger Li, MD, discussed the use of the CG0070 in combination with pembrolizumab and nivolumab for patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.